Top Suppliers:I want be here
Related CAS#:
170809-51-5 681260-70-8
31078-12-3 81083-98-9
2840-17-7 2061344-88-3
211364-78-2 1830-73-5
78331-26-7 1238673-32-9

170809-51-5

170809-51-5 structure
170809-51-5 structure
  • Name: Astressin TFA
  • Chemical Name: astressin
  • CAS Number: 170809-51-5
  • Molecular Formula: C161H269N49O42
  • Molecular Weight: 3563.16000
  • Catalog: Peptides
  • Create Date: 2018-06-13 05:31:49
  • Modify Date: 2024-01-02 12:51:50
  • Astressin is a potent corticotropin releasing factor (CRF) antagonist.
Name astressin
Synonyms Astressin
M.W. 3563.24 C161H269N49O42
[D-Phe12,Nle21,38,Glu30
ASTRESSIN TRIFLUOROACETATE SALT
Description Astressin is a potent corticotropin releasing factor (CRF) antagonist.
Related Catalog
In Vitro Astressin has low affinity for the CRF binding protein and high affinity (Ki=2 nM) for the cloned pituitary receptor. Astressin shows high affinity for cloned human CRF-RA1 stably expressed in CHO cells and high potency to inhibit ACTH secretion[1].
In Vivo Astressin is significantly more potent than any previously tested antagonist in reducing hypophyseal corticotropin (ACTH) secretion in stressed or adrenalectomized rats. Low doses of astressin (30 μg and 100 μg per kg) administered i.v. still produce a significant decrease in ACTH levels at 45 and 90 min, respectively[1]. Astressin significantly reverses the anxiogenic-like response induced by both social stress and ICV rat/humanCRF (r/hCRF) on the elevated plus-maze, but fails to block the effects of r/hCRF-induced locomotor activity in a familiar environment[2]. Intracerebroventricular infusion of the peptide both 30 min before and 10 min after seizures decreases damage in some hippocampal cell fields by as much as 84%, a magnitude of protection greater than reported for other CRF antagonists against other models of necrotic neuronal injury. Astressin protects even if administered only 10 min following excitotoxin exposure[3].
Animal Admin Rats: Rat diet is supplemented with oranges, and their water contained 0.9% NaCl. They are equipped with indwelling jugular cannulae 48 h prior to the i.v. injection of either vehicle or astressin. Astressin is first diluted in sterile, distilled, apyrogenic water, and the pH is adjusted to 7.0. Further dilutions are made in 0.04 M phosphate buffer, pH 7.4, containing 0.1% bovine serum albumin and 0.01% ascorbic acid. Blood samples are obtained immediately before treatment, as well as 15-120 min later. Decanted plasma samples are frozen until assayed for ACTH concentrations[1].
References

[1]. Gulyas J, et al. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10575-9.

[2]. Spina MG, et al. Behavioral effects of central administration of the novel CRF antagonist astressin in rats. Neuropsychopharmacology. 2000 Mar;22(3):230-9.

[3]. Maecker H, et al. Astressin, a novel and potent CRF antagonist, is neuroprotective in the hippocampus when administered after a seizure. Brain Res. 1997 Jan 2;744(1):166-70.
Molecular Formula C161H269N49O42
Molecular Weight 3563.16000
Exact Mass 3561.04000
PSA 1489.66000
LogP 9.58910
Storage condition 2-8℃
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR NONH for all modes of transport

Chemsrc provides CAS#:170809-51-5 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 170809-51-5 | Chemsrc address: https://m.chemsrc.com/en/baike/753753.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved